Aqilion's CEO: "We are driven by dealmaking and scientific data"
With four independent programmes in its pipeline, the Swedish biotech Aqilion is positioned for a series of significant upcoming milestones. CEO Sarah Fredriksson joined BioStock’s studio to share updates on the progress of these programmes, key takeaways from the pre-IND meeting with the FDA, and the lasting impact of Aqilion’s previous major deal with Merck — both within the organisation and in its drive to forge new collaborations.
00:00 Introduction
00:22 AQ280 background
01:53 The benefits of AQ280 within EoE
03:30 Phase IIa/IIb
04:00 Pre-IND meeting
05:32 Phase II financing
06:58 Regaining the TAK1 programme from Merck
08:55 AQ312 within ulcerative colitis
09:52 Preclinical data with AQ312
10:50 PKCTheta programme
12:35 Upcoming milestones
Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn: / biostock
Facebook: / biostock.se
https://www.biostock.se/
#BioStock #LifeScience #aqilion
About BioStock
BioStock is Scandinavia's leading digital news and analysis service, exclusively focusing on the Life Science sector. Our primary editorial office and tv-studio are found at Medicon Village in Lund, one of Sweden's foremost innovation clusters for life science companies.